Skip to main
  1. Stocks
  2. Ardent Health Partners LLC
  3. Forecast
ARDT

ARDT Stock Forecast & Price Target

ARDT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 40%
Hold 20%
Sell 10%
Strong Sell 0%

Bulls say

Ardent Health is benefiting from improving volume trends and disciplined cost control, with 3Q26 adjusted admissions up 2.9% year over year, ER visits turning positive, and surgery trends improving sequentially even as management kept guidance prudent amid a fluid sector backdrop. Its operating leverage is being reinforced by meaningful expense gains, including SWB down 4.3% to 39.9% of revenue, contract labor falling 45% year over year to 2.0% of SWB, and DSO improving by about four days, while 3Q cash generation reached $122MM despite a delayed $37MM New Mexico supplemental payment. The company’s strong balance sheet, with $766MM of cash and lease-adjusted net leverage of 2.5x, supports a credible M&A runway in attractive mid-sized urban markets, where its joint venture strategy and outpatient expansion can compound margins and market share.

Bears say

Ardent Health is facing a weak fundamental outlook because its downside case assumes it cannot meet ambulatory expansion or organic volume targets as patient engagement falters, which would leave 2027E adjusted EBITDAR about 10% below current estimates and the valuation multiple compressed to 4.5x, well below peer levels. Its risk profile is further pressured by government reimbursement uncertainty, especially Medicare, plus operational exposure to nursing and physician labor costs and availability, M&A execution risk, and heavy operating lease obligations tied to a JV-oriented structure with limited facility ownership. Concentration in Texas and Oklahoma, where 34% and 27% of beds are located, also amplifies downside risk if volumes slow, claims denials rise, or other costs accelerate and prevent margin expansion.

ARDT has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.

ARDT Analyst Forecast & Price Prediction

Get the latest ARDT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ARDT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardent Health Partners LLC (ARDT) Forecast

Analysts have given ARDT a Buy based on their latest research and market trends.

According to 10 analysts, ARDT has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardent Health Partners LLC (ARDT)


ARDT Analyst Forecast & Price Prediction

Get the latest ARDT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ARDT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ARDT stock data and trends